Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8061)	12/15/1998 7:12:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

New twist to the ongoing "superbug" mantra being generated by the press, combines the "Internet" mantra. Of course you and I, after having studied hundreds of abstracts and publications by independent clinicians, believe there is a possibility Neuprex can have a significant therapeutic benefit to the treatment of many of these. And you and I realize that physicians have a network and if a drug is overwhelmingly beneficial in a treatment, they will pass that information along. Of course all of this is relative to the fact that Neuprex is still pending FDA approval.